Literature DB >> 27129318

Treatment of patients with immune thrombocytopenia admitted to the emergency room.

Işıl Bavunoğlu1, Ahmet Emre Eşkazan2, Muhlis Cem Ar3, Mahir Cengiz1, Serap Yavuzer1, Ayşe Salihoğlu2, Şeniz Öngören2, Aydın Tunçkale1, Teoman Soysal2.   

Abstract

Immune thrombocytopenia (ITP) is the most frequent cause of acquired thrombocytopenia. In adult ITP patients, corticosteroids and intravenous immunoglobulin (IVIg) are used as first-line treatment. The aim of the present study was to investigate retrospectively the demographic and etiologic characteristics of patients with ITP admitted to the emergency room at our hospital. Seventy-five adult patients with ITP were included, and demographic data, bleeding characteristics, etiologic features and responses to treatments were evaluated retrospectively. Fifty-six patients (75 %) were female, and the median age was 43 years. Eighteen patients had a history of ITP, whereas in 57, thrombocytopenia was identified for the first time. During admission, the median platelet count was 5 × 10(9)/L. Cutaneous and/or mucosal bleeding was the most common clinical feature. High-dose dexamethasone was administered in 60 episodes, whereas IVIg and conventional-dose methylprednisolone were used in nine and six episodes, respectively. The overall response rate of the entire cohort following first-line treatments was 67 %, and complete remission was achieved in 31 patients, 19 patients achieved partial remission, and 25 patients were non-responders. In cases with life-threatening bleeding, concomitant infection, post-traumatic bleeding and need for emergency surgery, IVIg can be used as the first line of treatment option in addition to platelet transfusions.

Entities:  

Keywords:  Conventional-dose methylprednisolone; Emergency room; High-dose dexamethasone; Immune thrombocytopenia; Intravenous immunoglobulin

Mesh:

Substances:

Year:  2016        PMID: 27129318     DOI: 10.1007/s12185-016-2003-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.

Authors:  J E Portielje; R G Westendorp; H C Kluin-Nelemans; A Brand
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

2.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

Authors: 
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 3.  Common variable immune deficiency: reviews, continued puzzles, and a new registry.

Authors:  Charlotte Cunningham-Rundles; Adina Kay Knight
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

5.  High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial.

Authors:  Yu Wei; Xue-bin Ji; Ya-wen Wang; Jing-xia Wang; En-qin Yang; Zheng-cheng Wang; Yu-qi Sang; Zuo-mu Bi; Cui-ai Ren; Fang Zhou; Guo-qiang Liu; Jun Peng; Ming Hou
Journal:  Blood       Date:  2015-10-19       Impact factor: 22.113

6.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age.

Authors:  H Frederiksen; K Schmidt
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

7.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.

Authors:  J Pizzuto; R Ambriz
Journal:  Blood       Date:  1984-12       Impact factor: 22.113

8.  Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.

Authors:  Maria Gabriella Mazzucconi; Paola Fazi; Sayla Bernasconi; Giulio De Rossi; Giuseppe Leone; Luigi Gugliotta; Nicola Vianelli; Giuseppe Avvisati; Francesco Rodeghiero; Angela Amendola; Carlo Baronci; Cecilia Carbone; Stefano Quattrin; Giuseppe Fioritoni; Giulio D'Alfonso; Franco Mandelli
Journal:  Blood       Date:  2006-10-31       Impact factor: 22.113

Review 9.  Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms.

Authors:  Masataka Kuwana
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation.

Authors:  J Bussel
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

View more
  1 in total

1.  Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira - 2018.

Authors:  Margareth Castro Ozelo; Marina Pereira Colella; Erich Vinícius de Paula; Ana Clara Kneese Virgilio do Nascimento; Paula Ribeiro Villaça; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.